R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.

Biotech R&D: Xencor vs. Protagonist's Decade of Innovation

__timestampProtagonist Therapeutics, Inc.Xencor, Inc.
Wednesday, January 1, 2014745900018516000
Thursday, January 1, 20151183100034140000
Friday, January 1, 20162570500051872000
Sunday, January 1, 20174618100071772000
Monday, January 1, 20185949700097501000
Tuesday, January 1, 201965003000118590000
Wednesday, January 1, 202074506000169802000
Friday, January 1, 2021126006000192507000
Saturday, January 1, 2022126215000199563000
Sunday, January 1, 2023120161000253598000
Loading chart...

Igniting the spark of knowledge

R&D Spending: A Tale of Two Innovators

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Protagonist Therapeutics, Inc. and Xencor, Inc. have been at the forefront of this race. Since 2014, Xencor has consistently outpaced Protagonist in R&D investment, with a notable 37% higher spending in 2023. This trend highlights Xencor's aggressive push towards groundbreaking therapies. Meanwhile, Protagonist has shown a steady increase in its R&D budget, peaking in 2022 with a 17-fold increase from 2014. This strategic allocation underscores their dedication to advancing peptide-based therapeutics. As both companies continue to innovate, their R&D investments will likely play a pivotal role in shaping the future of biotech breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025